BackAmylyx Pharmaceuticals Overview
Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Target Price

Where could AMLX trade next? Consensus target price: $43.

Get informed when a big investor buys or sells

+ Follow

Share Price

$30.61

Average Target Price

$43.0840.8% upside

12 analysts in the last 4 months

High: $57 | Low: $24

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-27GuggenheimSeamus Fernandez$5786.2% upsideOpen
2026-08-19Guggenheim$5579.7% upsideOpen
2026-08-18Mizuho SecuritiesGraig Suvannavejh$4237.2% upsideOpen
2026-08-18Robert W. Baird$5269.9% upsideOpen
2026-08-18H.C. WainwrightAndrew Fein$5579.7% upsideOpen
2026-08-18UBS$5579.7% upsideOpen
2026-08-18UBS$4547% upsideOpen
2026-08-17Mizuho SecuritiesGraig Suvannavejh$302% downsideOpen
2026-08-07Robert W. Baird$288.5% downsideOpen
2026-07-20Mizuho SecuritiesGraig Suvannavejh$2421.6% downsideOpen
2026-06-25Guggenheim$4030.7% upsideOpen
2026-06-08H.C. WainwrightAndrew Fein$3411.1% upsideOpen
2026-04-28Mizuho SecuritiesGraig Suvannavejh$2131.4% downsideOpen
2026-02-19Mizuho Securities$1937.9% downsideOpen
2026-02-10H.C. WainwrightAndrew Fein$288.5% downsideOpen
2025-10-29Mizuho Securities$1647.7% downsideOpen
2025-10-16Robert W. BairdJoel Beatty$1937.9% downsideOpen
2025-09-15GuggenheimSeamus Fernandez$2518.3% downsideOpen
2025-06-24GuggenheimSeamus Fernandez$1744.5% downsideOpen
2025-05-06Leerink PartnersMarc Goodman$1067.3% downsideOpen
2024-11-18Robert W. BairdJoel Beatty$1164.1% downsideOpen
2024-10-23Bank of America SecuritiesGeoff Meacham$1067.3% downsideOpen
2024-10-18H.C. WainwrightAndrew Fein$873.9% downsideOpen
2024-10-18Leerink PartnersMarc Goodman$486.9% downsideOpen
2024-05-14Mizuho SecuritiesGraig Suvannavejh$390.2% downsideOpen
2024-04-11Robert W. BairdJoel Beatty$390.2% downsideOpen
2024-04-04Deutsche BankNeena Bitritto-Garg$486.9% downsideOpen
2024-03-17Mizuho SecuritiesGraig Suvannavejh$486.9% downsideOpen

Amylyx Pharmaceuticals (AMLX) FAQ

Amylyx Pharmaceuticals posts a target price of $43. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $43 for AMLX means covering analysts, on average, see the stock 40.8% upside of $30.61 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for AMLX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Amylyx Pharmaceuticals's other metric pages and overview cover the third.